RESUMO
REFINE was a 12-month, prospective, open-label study in 356 patients receiving de novo liver transplantation for hepatitis C virus (HCV) cirrhosis, randomized to cyclosporine A (CsA) or tacrolimus with (i) no steroids, IL-2 receptor antibody induction and mycophenolic acid, or (ii) slow steroid tapering. The primary analysis population based on availability of liver biopsies comprised 165 patients (88 CsA, 77 tacrolimus). There was no difference in the primary endpoint, fibrosis stage ≥2 at 12 months, which occurred in 63/88 CsA-treated patients (71.6%) and 52/77 tacrolimus-treated patients (67.5%) (odds ratio [OR] 1.11; 95% CI 0.56, 2.21; p = 0.759). Similarly, no significant between-group difference occurred at month 24 (OR 1.15; 95% CI 0.47, 2.80; p = 0.767). Among steroid-free patients, fibrosis score ≥2 was significantly less frequent with CsA versus tacrolimus at month 12 (7/37 [18.9%] vs. 16/38 [42.1%]; p = 0.029). HCV viral load was similar in both the tacrolimus- and CsA-treated cohorts. Mean blood glucose was significantly higher with tacrolimus from day 15 onward. Biopsy-proven acute rejection, graft loss and death were similar. These results showed no differences in posttransplant HCV-induced liver fibrosis between patients treated with CsA or tacrolimus in steroid-containing regimens, whereas CsA in steroid-free protocols was associated with reduced severity of fibrosis progression at 1 year posttransplant.
Assuntos
Ciclosporina/uso terapêutico , Rejeição de Enxerto/tratamento farmacológico , Hepatite C/cirurgia , Imunossupressores/uso terapêutico , Cirrose Hepática/prevenção & controle , Transplante de Fígado , Tacrolimo/uso terapêutico , Feminino , Seguimentos , Rejeição de Enxerto/etiologia , Sobrevivência de Enxerto/efeitos dos fármacos , Hepacivirus/patogenicidade , Hepatite C/complicações , Hepatite C/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Taxa de SobrevidaRESUMO
Diagnosis and prediction of the severity of hepatitis C virus recurrence (HCVrec) after liver transplantation (LT) remain a challenge. MicroRNAs have been recently recognized as potential disease biomarkers. Archival liver biopsy samples from 43 HCV+ LT recipients were collected at clinical HCVrec time and at 3 years post-LT. Patients were classified as progressors (P = F0/F1) or nonprogressors (NP = F3/F4) according to the severity of fibrosis on the 3-year biopsy. Training (n = 27) and validation (n = 16) sets were defined. RNA was isolated from all biopsies at clinical HCVrec time, labeled and hybridized to miRNA-arrays. Progressors versus nonprogressors were compared using the two-sample t-test. A p-value ≤0.01 was considered significant. The ingenuity pathway analysis tool was used for microRNA and miRNA:mRNA ontology data integration. Nine microRNAs were differentially expressed between groups. A supervised cluster analysis separated samples in two well-defined groups (progressors vs. nonprogressors). Pathway analysis associated those microRNAs with hepatitis, steatosis, fibrosis, cirrhosis and T cell-related immune response. Data integration identified 17 genes from a previous genomic study as 9-microRNAs signature targets. Seven microRNAs were successfully validated in the validation set using QPCR. We have identified a 9-microRNA signature able to identify early post-LT patients at high risk of severe HCVrec during long-term follow-up.
Assuntos
Hepatite C/cirurgia , Cirrose Hepática/diagnóstico , Cirrose Hepática/cirurgia , Transplante de Fígado/efeitos adversos , MicroRNAs/genética , Complicações Pós-Operatórias , Adulto , Idoso , Biomarcadores/análise , Biomarcadores/metabolismo , Progressão da Doença , Feminino , Seguimentos , Perfilação da Expressão Gênica , Rejeição de Enxerto , Sobrevivência de Enxerto , Hepacivirus/patogenicidade , Hepatite C/complicações , Hepatite C/virologia , Humanos , Cirrose Hepática/complicações , Cirrose Hepática/etiologia , Cirrose Hepática/virologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Análise de Sequência com Séries de Oligonucleotídeos , Prognóstico , Estudos Prospectivos , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Recidiva , Estudos Retrospectivos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de RiscoRESUMO
Severe liver involvement requiring liver transplantation is a rare complication in systemic lupus erythematosus (SLE), but very few cases have been reported. We describe a 39-year-old woman with SLE who underwent successful liver transplantation due to acute liver failure. The patient persisted without reactivation of SLE and with good long-term survival. Management and diagnosis considerations are reviewed.
Assuntos
Falência Hepática/etiologia , Falência Hepática/cirurgia , Transplante de Fígado , Lúpus Eritematoso Sistêmico/complicações , Adulto , Feminino , Humanos , Resultado do TratamentoRESUMO
During a 2-yr period 15 patients (17 episodes) with variceal bleeding (VB) and 7 with cirrhosis and acute gastroduodenal haemorrhage (GDH) received intravenous somatostatin (250 mcg per hr after a bolus of 250 mcg). Initial control of bleeding was achieved in 13 (76%) with VB and in all with GDH. Three of the 4 patients with VB and 2 with GDH who rebled during treatment were controlled increasing the infusion to 500 mcg/hr. Patients with VB received somatostatin for 24 hrs, time selected for initiating injection sclerotherapy, and those with GDH for 48-72 hrs. At 24 hrs 71% of patients with VB and all with GDH were free of bleeding. Combining different therapies VB was controlled in 16 of the 17 episodes (94%) with only one death. No complications were observed in any of the 22 patients treated.
Assuntos
Varizes Esofágicas e Gástricas/terapia , Hemorragia Gastrointestinal/prevenção & controle , Hipertensão Portal/complicações , Soluções Esclerosantes/uso terapêutico , Somatostatina/uso terapêutico , Adulto , Idoso , Emergências , Varizes Esofágicas e Gástricas/complicações , Feminino , Hemorragia Gastrointestinal/etiologia , Humanos , Cirrose Hepática/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
Recurrence of viral infection and hepatitis is a common problem for patients undergoing LT for hepatitis B or hepatitis C. In patients with hepatitis B who do not receive immunoprophylaxis, recurrence of HBsAg positivity is virtually universal and is usually associated with rapidly progressive hepatitis that jeopardizes long-term patient and allograft survival. HCV infection recurs in 80% to 100% of patients, but only 50% develop histologic features of hepatitis, which are generally mild and do not significantly decrease life survival. Long-term HBIg prophylaxis is currently the only effective strategy to prevent or modify HBV recurrence. At present, there is no effective prophylaxis for recurrence of HCV infection. Preliminary results suggest that interferon therapy may benefit a minority of patients with either recurrent HBV or HCV infection after LT. Hepatitis B should not be regarded as a contraindication for LT. However, until an effective and readily available therapy is developed to prevent recurrence, HBsAg-positive patients should undergo transplantation under experimental protocols. Hepatitis C is also not a contraindication for LT. Although recurrent hepatitis C is usually mild and slowly progressive, severe forms of hepatitis requiring retransplantation have been increasingly reported. Long-term follow-up studies are needed to define the natural history of recurrent HCV infection after LT and its impact on allograft and patient survival.
Assuntos
Hepatite B/etiologia , Hepatite C/etiologia , Transplante de Fígado/efeitos adversos , Antígenos Virais/imunologia , Antivirais/uso terapêutico , DNA Viral/análise , Hepacivirus/fisiologia , Hepatite B/terapia , Vírus da Hepatite B/fisiologia , Hepatite C/terapia , Humanos , Imunização Passiva/métodos , Transplante de Fígado/mortalidade , Prevenção Secundária , Taxa de Sobrevida , Resultado do Tratamento , Replicação Viral/efeitos dos fármacosRESUMO
Hepatitis C virus (HCV) RNA polymerase chain reaction (PCR) is widely used for diagnosis of HCV infection and evaluation of therapy. The sensitive hepatitis B virus (HBV) DNA PCR is often reserved for detection of quantities of HBV DNA that are insufficient for hybridization. Application of both PCR techniques is limited by their labor-intensity, potential for contamination, and substantial time required for analysis. To study HCV and HBV infections, occurring alone or in combination, we developed a combined one-step PCR method to detect HCV RNA and HBV DNA in a single serum specimen using oligoprimers from the HCV 5' untranslated region and the HBV preS/S region. Specificity of the HBV and HCV PCR products was confirmed on the basis of their molecular sizes in positive samples, Southern blot hybridization, and negative controls. The sensitivities of the combined PCR were assessed using samples containing a wide range of defined amounts of HBV DNA and HCV RNA and were comparable with those obtained with conventional HBV DNA or HCV RNA PCR methods. The sensitivity of the combined method was further validated by the 100% concordance between results of its HBV and HCV components and those of conventional PCR methods in patients with HBV and/or HCV infections. The combined one-step HBV/HCV PCR is a sensitive, specific, rapid, and cost-effective method, especially suited for epidemiological screening and clinical diagnosis of HBV and HCV infections occurring alone or in combination.
Assuntos
DNA Viral/análise , Hepacivirus/genética , Vírus da Hepatite B/genética , Reação em Cadeia da Polimerase/métodos , RNA Viral/análise , Sequência de Bases , Hepatite B/diagnóstico , Hepatite C/diagnóstico , Humanos , Dados de Sequência Molecular , Sensibilidade e EspecificidadeRESUMO
Recurrent hepatitis C infection after orthotopic liver transplantation (OLT) is frequent and may occur as early as a few weeks postoperatively. Early histopathological features of recurrent hepatitis C virus (HCV) infection may be modified by immunosuppressive therapy and can be difficult to differentiate from acute allograft rejection (AAR). Thus, we retrospectively compared histopathological features of liver biopsy specimens from two carefully selected patient groups: one with unequivocal recurrent hepatitis C, the other with unequivocal AAR. Index biopsy specimens obtained at the time of the appearance of liver test abnormalities after OLT and all serial liver biopsy specimens (2 to 13 per patient) were assessed under code and scored semiquantitatively for 44 histopathological variables. The index biopsy specimens from patients with recurrent HCV infection and AAR index biopsies (AAR-Ib) differed significantly (P < .05) for 11 features (10 features were statistically associated with AAR and 1 with early recurrence of HCV infection). Statistically significant features associated with AAR included bile duct injury with overlapping nuclei, lymphocytic infiltrates and necrosis, endothelialitis, portal inflammatory infiltrates containing eosinophils and polymorphonuclear leukocytes, hepatocyte mitoses, and zone 3 canalicular cholestasis. In contrast, the only statistically significant feature associated with early recurrent HCV was sinusoidal dilatation. Stepwise discriminant analysis showed that the presence of eosinophils in the portal inflammatory infiltrate, bile duct necrosis, and bile duct lymphocytic infiltrates were independently associated with AAR. However, serial biopsy specimens from patients with recurrent HCV infection showed statistically significant progression in scores for portal inflammation, portal lymphoid aggregates, and lobular inflammation. We conclude that (1) multiple histopathological features are associated with AAR; (2) early recurrent HCV infection is characterized by elevated alanine aminotransferase levels, positive HCV RNA by polymerase chain reaction (PCR), and absence of diagnostic histopathological features; and (3) serial biopsies are needed to demonstrate progression of histopathological features of recurrent hepatitis C.
Assuntos
Rejeição de Enxerto/patologia , Hepatite C/patologia , Transplante de Fígado/efeitos adversos , Doença Aguda , Adulto , Biópsia , Eosinófilos/patologia , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/prevenção & controle , Hepacivirus/genética , Hepacivirus/imunologia , Hepatite C/etiologia , Anticorpos Anti-Hepatite C/análise , Humanos , Imunossupressores/uso terapêutico , Fígado/patologia , Reação em Cadeia da Polimerase , RNA Viral/análise , Recidiva , Estudos Retrospectivos , Transplante HomólogoRESUMO
Ascitic fluid alpha 1-antitrypsin (AF-AAT) was compared with ascitic fluid total protein (AF-TP) and the serum-ascites albumin gradient (SAAG) in the differential diagnosis of ascites. The study included 82 consecutive patients of which 42 had cirrhosis, 8 hepatoma (with cirrhosis), and 27 malignant ascites (peritoneal 18, liver 9). The concentration of AF-AAT (milligrams per deciliter) was significantly elevated (P less than 0.001) in hepatoma (174 +/- 123), malignant liver disease (232 +/- 119) and peritoneal neoplasms (376 +/- 106) in comparison with cirrhotics (66 +/- 33). In separating ascites caused by cirrhosis or malignancy, AF-AAT (discriminating limit of 120 mg/dl) had a 96% sensitivity, 95% specificity, and 96% diagnostic efficacy, which was superior to the 87% observed for AF-TP and 86% for the SAAG. Similar results were obtained for the A/S AAT ratio but this test was not available in all patients. AF-AAT was particularly useful in patients with malignancy causing portal hypertension as assessed by SAAG (hepatoma, malignant liver disease). We conclude that AF-AAT may be a valuable parameter in the differential diagnosis of ascites.
Assuntos
Líquido Ascítico/análise , alfa 1-Antitripsina/análise , Ascite/etiologia , Carcinoma Hepatocelular/complicações , Diagnóstico Diferencial , Humanos , Cirrose Hepática/complicações , Neoplasias Hepáticas/complicações , Neoplasias Peritoneais/complicaçõesRESUMO
Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than genotype 1b, have been identified that accurately predict these dissimilar outcomes. The natural history of recurrent hepatitis C varies. Historically, it has been regarded as generally benign. However, with increasing numbers of patients transplanted for hepatitis C it is now clear that a subgroup of patients develops severe progressive cholestatic hepatitis associated with allograft failure and death without retransplantation. Within 5 years following OLT, approximately 15-20% of patients progress to chronic active hepatitis and another 15-20% become cirrhotic. A minority of patients develop glomerulopathy or vasculitis, which are often associated with cryoglobulinaemia. The impact of immunosuppressive medications and rejection episodes on histopathological recurrence of progressive hepatitis C remains controversial and requires further studies. Although actuarial survival rates of patients transplanted for hepatitis C differ among transplantation centres, it appears that histopathological recurrence of hepatitis C does have an adverse impact on actuarial survival compared to the survival of patients transplanted for autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis and metabolic liver diseases. When allograft failure develops in patients with recurrent hepatitis C, retransplantation is indicated, even though recent reports indicate that mortality may be increased, especially with concurrent renal insufficiency.
Assuntos
Hepatite C/mortalidade , Transplante de Fígado , Complicações Pós-Operatórias , Hepatite C/epidemiologia , Humanos , Morbidade , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/mortalidade , Recidiva , Reoperação , Fatores de RiscoRESUMO
Autoimmune hepatitis is a form of chronic liver disease characterized by progressive hepatocellular inflammation, which usually responds to treatment with corticosteroids. However, 10% of patients with autoimmune hepatitis are refractory to corticosteroids and develop progressive liver disease and cirrhosis. We describe five patients with autoimmune hepatitis who did not respond to conventional corticosteroids and azathioprine therapy who were then treated with cyclosporine A. Cyclosporine A was started at 2-3 mg/kg/day and induced biochemical remission in four of five patients within 3 months. One of the four responders relapsed within 1 month of discontinuing cyclosporine on two occasions. Each time, liver tests promptly normalized after reinitiation of cyclosporine. Two responders were managed with cyclosporine alone. The single patient who did not respond to cyclosporine developed progressive liver failure, underwent orthotopic liver transplantation, and subsequently died of disseminated cytomegalovirus infection. Cyclosporine was generally well tolerated and none of the patients developed renal insufficiency. These data and review of 11 cases in the literature show that cyclosporine can induce remission of liver disease in patients with autoimmune hepatitis who are refractory to corticosteroids.
Assuntos
Ciclosporina/uso terapêutico , Hepatite Autoimune/terapia , Imunossupressores/uso terapêutico , Adulto , Resistência a Medicamentos , Feminino , Glucocorticoides/uso terapêutico , Hepatite Autoimune/diagnóstico , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Prednisona/uso terapêuticoRESUMO
Lymphomatous involvement of the liver may present as acute liver failure but is an absolute contraindication for liver transplantation. Therefore it is imperative to diagnose such patients since survival in this group is poor and recurrence is high. We describe two patients with acute liver failure referred for liver transplantation whose diagnostic testing revealed hepatic lymphoma. These cases underscore the importance of considering lymphoma in the differential diagnosis of acute liver failure prior to liver transplant.
Assuntos
Doença de Hodgkin/complicações , Falência Hepática Aguda/diagnóstico , Transplante de Fígado , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Adolescente , Adulto , Contraindicações , Feminino , Doença de Hodgkin/patologia , Humanos , Fígado/patologia , Falência Hepática Aguda/etiologia , Falência Hepática Aguda/cirurgia , Neoplasias Hepáticas/complicações , MasculinoRESUMO
We describe three patients referred for orthotopic liver transplantation with liver failure and portal hypertension who were found to have malignant vascular tumors: two patients with angiosarcoma and one patient with epithelioid hemangioendothelioma. Their clinical presentation mimicked decompensated chronic liver disease. None had tumor masses on computed tomography and ultrasonography. Massive tumor involvement of the liver was identified in the two patients studied by magnetic resonance imaging. Pathological examination of the explanted liver at the time of transplantation in one patient and autopsy in a second patient showed angiosarcoma. Laparoscopic liver biopsies in the third patient showed epithelioid hemangioendothelioma. The vascular origin of the tumor was established by histopathologic examination and confirmed with immunohistochemistry. Malignant vascular tumors of the liver should be included in the differential diagnosis of liver failure of unclear etiology.
Assuntos
Hipertensão Portal/etiologia , Falência Hepática/etiologia , Neoplasias Hepáticas/complicações , Neoplasias de Tecido Vascular/complicações , Adulto , Biópsia , Diagnóstico Diferencial , Evolução Fatal , Hemangioendotelioma Epitelioide/complicações , Hemangioendotelioma Epitelioide/diagnóstico , Hemangiossarcoma/complicações , Hemangiossarcoma/diagnóstico , Humanos , Hipertensão Portal/diagnóstico , Hipertensão Portal/cirurgia , Laparoscopia , Falência Hepática/diagnóstico , Falência Hepática/cirurgia , Neoplasias Hepáticas/diagnóstico , Transplante de Fígado , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neoplasias de Tecido Vascular/diagnóstico , Tomografia Computadorizada por Raios XRESUMO
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. The aim of this study was to determine the prevalence of HBV S gene mutations in liver transplant recipients who developed recurrent hepatitis B despite HBIG prophylaxis, and to determine if these mutations can revert after withdrawal of HBIG. The entire S gene sequences in pre- and posttransplant sera from 20 patients who developed recurrent hepatitis B despite HBIG prophylaxis were compared. Ten (50%) patients had 18 amino acid substitutions involving the 'a' determinant in the posttransplant samples. These mutations were absent in 93% of the pretransplantation clones analyzed. There was a significant correlation between the development of mutations in the 'a' determinant region and the duration of HBIG therapy. Most of the mutations result in changes in predicted antigenicity of the S protein. During follow-up, mutations in 14 (78%) of 18 affected codons in the 'a' determinant region reverted back to the pretransplantation sequences; only 1 codon had a de novo change after the withdrawal of HBIG. Two control patients who did not receive HBIG had no change in the 'a' determinant in their posttransplantation samples. These data support the hypothesis that mutations in the S gene were induced or selected by immune pressure exerted by HBIG. HBV S mutants may play a role in HBV reinfection in liver transplant recipients who received HBIG prophylaxis.
Assuntos
Antígenos de Superfície da Hepatite B/genética , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Hepatite B/prevenção & controle , Hepatite B/virologia , Imunização Passiva , Transplante de Fígado , Mutação , Adulto , Sequência de Aminoácidos , Sequência de Bases , Feminino , Hepatite B/imunologia , Antígenos de Superfície da Hepatite B/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Complicações Pós-Operatórias , Recidiva , Fatores de TempoRESUMO
OBJECTIVE: To describe the hepatotoxicity associated with ingestion of the Chinese herbal product Jin Bu Huan Anodyne Tablets (Lycopodium, serratum) and to propose possible mechanisms of injury. DESIGN: Retrospective analysis. SETTING: Academic hepatology units and private practice facilities. PATIENTS: Seven previously healthy patients. MEASUREMENTS: Clinical, laboratory, radiologic, and histologic studies. RESULTS: Acute hepatitis occurred after a mean of 20 weeks (range, 7 to 52 weeks) of Jin Bu Huan ingestion and resolved in six patients within a mean of 8 weeks (range, 2 to 30 weeks); another patient is currently improving. Hepatitis was associated with symptoms of fever, fatigue, nausea, pruritus, and abdominal pain and with signs of jaundice and hepatomegaly. Biopsy specimens showed that one patient had hepatitis with eosinophils (consistent with a drug reaction) and the other had mild hepatitis, moderate fibrosis, and microvesicular steatosis. Decreasing the Jin Bu Huan dose in one patient improved liver test results. Reusing Jin Bu Huan in two other patients caused abrupt recrudescence of hepatitis. CONCLUSION: Jin Bu Huan can cause liver injury. Although the hepatotoxic mechanisms are not defined, they may include hypersensitive or idiosyncratic reactions or direct toxicity to active metabolites. Hepatotoxicity caused by herbal products underscores the toxicity caused by herbal products underscores the importance of national surveillance programs and quality control of the manufacture of these products.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/etiologia , Medicamentos de Ervas Chinesas/efeitos adversos , Doença Aguda , Adulto , Biópsia , Doença Hepática Induzida por Substâncias e Drogas/diagnóstico , Medicamentos de Ervas Chinesas/normas , Feminino , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Controle de Qualidade , Estudos RetrospectivosRESUMO
The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia. We assessed serum HCV RNA using polymerase chain reaction (PCR) and oligoprimers from the 5'UTR of the HCV genome in 26 consecutive patients with FHF. Another laboratory independently performed PCR on 21 of the serum samples using different oligoprimers from the 5'UTR and NS3 region of the HCV genome. Serum HCV RNA was detected in two of seven (28%) patients with hepatitis B, 9 of 15 (60%) with an indeterminate cause, and in none with hepatitis A (n = 2) or drug-induced hepatotoxicity (n = 2). HCV RNA PCR results were concordant between both laboratories in 17 of 21 (81%) of samples. In patients with an indeterminate cause, HCV RNA positivity was significantly associated with the transmission risk factor of low socioeconomic status and Hispanic ethnicity. Eighteen patients underwent liver transplantation (LT) and 15 (83%) survived. Among patients with FHF of indeterminate cause, recurrent or acquired HCV infection after transplantation occurred in three of five (60%) and one of four (25%) patients, respectively. Three of four (75%) patients with hepatitis C virus infection post-LT also developed histologic hepatitis. HCV appears to be the causative agent of a substantial number of cases of FHF classified as indeterminate in the Los Angeles area. Differences in patient populations or risk factors may explain the discordant incidences of HCV infection in FHF observed among different programs.
Assuntos
Hepacivirus/isolamento & purificação , Encefalopatia Hepática/virologia , Hepatite C/complicações , RNA Viral/sangue , Adolescente , Adulto , Sequência de Bases , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Fatores de RiscoAssuntos
Hepatite B/cirurgia , Transplante de Fígado , Hepatite B/imunologia , Hepatite B/prevenção & controle , Anticorpos Anti-Hepatite B/uso terapêutico , Antígenos de Superfície da Hepatite B/análise , Antígenos E da Hepatite B/imunologia , Hepatite D/complicações , Humanos , Recidiva , Superinfecção/complicaçõesRESUMO
Durante un período de 2 años se evaluó utilidad de la somatostatina (250 mcg en bolo seguido de 250 mcg/h IV) en 17 episodios de hemorragia por várices esofágicas (VES) y 7 por lesiones agudas de la mucosa gastroduodenal (LAMG) en hipertensos portales diagnosticados por endoscopía de urgencia. Se obtuvo la hemostásia inicial (dentro de las 2 hs.) en el 76% de las VES y el 100% de las LAMG. Tres de los 4 pacientes con VES y los 2 con LAMG que recidivaron la hemorragia durante el tratamiento respondieron al duplicar la dosis de somatostatina. La hemostasia a las 24 hs., fue del 71% para las VES, iniciándose en ese momento la esclerosis endoscópica, y del 100% ára las LAMG. Con las combinación de distintas terapéuticas se controló la hemorragia en 16 de los 17 pacientes com VES (94%). En ningún caso se observaron efectos colaterales adjudicables a la somatostatina. De acuerdo a nuestros hallazgos la somatostatina es una opción terapéutica valiosa en el tratamiento de emergencia de la hemorragia digestiva alta en pacientes con hipertensión portal